Nicholas C Richardson (Nicholas Richardson)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 8

Top Topics

Drug Administration

Acute Myeloid Leukemia

Childhood Cancer

Top Venues

Cancer discovery

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Pediatric blood & cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Andrea C Baines, Maryam Sarraf Yazdy, Yvette L Kasamon, Rachel Ershler, Emily Y Jen, Bindu Kanapuru, Nicholas C Richardson, Ashley Lane, Theresa Carioti, Marc R Theoret, Richard Pazdur, Nicole J Gormley
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Nadia Howlader, Elad Sharon, Manami Bhattacharya, Lori A Ehrlich, Nicholas C Richardson, Nicole J Gormley, R Angelo de Claro, Amy E Wood, Angela B Smith, Kathleen A Cronin
The Impact of Improved Treatments on Survival of Adult US Leukemia Patients: 1990 - 2018. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2023)
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Abby Bronson, Marianne K Chase, Kimberly Fisher, Daniel Millar, Jane Perlmutter, Nicholas C Richardson
Mobilizing the clinical trial ecosystem to drive adoption of master protocols. Clinical trials (London, England) 19 (6) (2022)
Margret Merino, Yvette Kasamon, Hongshan Li, Lian Ma, Ruby Leong, Jiaxi Zhou, Gregory Reaman, Wiley Chambers, Nicholas C Richardson, Marc Theoret, Richard Pazdur, Nicole Gormley
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. Pediatric blood & cancer 69 (8) (2022)